ClinicalTrials.gg
Active, not recruitingNCT04427891Updated Apr 27, 2026

Characteristics of Abdominal Fluid in Patients With Diverticulitis Hinchey III or IV

An observational study in Perforated Diverticulitis, sponsored by Sahlgrenska University Hospital. Active, not recruiting at 1 site in Sweden. Per ClinicalTrials.gov, last updated 2026-04-27.

Sponsored by Sahlgrenska University Hospital · Observational

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as active, not recruiting.
Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
50
Sex
All
01

Study summary

Perforated diverticulitis of the colon can be complicated by peritonitis, either purulent or fecal. Both are life threatening conditions requiring emergency surgery. The background in terms of reasons for inflammation (diverticulitis) and perforation to develop is unknown. In this study we focus on specific changes associated with inflammation, both in tissues and of fecal and mucosal microbiota.

Read the detailed description

A prospective study of abdominal fluid, periferal blood, tissues as well as feces in Patients (perforated diverticulitis with peritonitis undergoing emergency surgery, Group I), and in Controls (patients operated due to colorectal cancer, Group II; patients with mild diverticulitis not needing surgery, Group III).

Immune acitvity in abdominal fluid and periferal blood by immunoassay of 92 individual proteins. mRNA expression of 96 specific genes in tissue samples. Quatification of bacterial diversity in feces and colon mucosa.

02

Conditions studied

  • Perforated Diverticulitis

Browse trials for

Keywords

  • perforated diverticulitis
  • peritonitis
  • protein changes
  • microbiota
03

In context

Peritonitis

167 studies on the registry are indexed under Peritonitis; 23 are open to participants now.

This study's planned enrollment of 50 is below the median of 137 across 55 observational studies indexed under Peritonitis.

Browse Peritonitis studies →

Lead sponsor

Sahlgrenska University Hospital is the lead sponsor of 263 studies on the registry; 68 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The aim is to study immune responses in patients with perforated divrticulitis leading to peritonitis and emergency surgery. This group will be compared with patients operated for colorectal cancer and patients with uncomplicated (mild) diverticulitis not undergoing surgery.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signs of perforated diverticulitis with peritonitis and decision to perform emergency surgery (Group I)
  • Signs of acute diverticulitis and no decision of emergency surgery (Group II)
  • Patients with colorectal cancer planned for elective surgery (Group III)

Exclusion criteria

Exclusion Criteria:

  • No surgery performed (Group I and III)
  • Withdrawn consent (any group)
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Group I

    Patients undergoing emergency surgery due to perforated diverticulitis with peritonitis. No intervention, samples from abdominal fluid, blood, tissue, feces

  • Group II

    Patients with colorectal cancer undergoing elective surgery. No intervention. Samples as for Group I

  • Group III

    Patients with mild diverticulitis, not undergoing surgery. No intervention. Samples from blood and feces.

06

What researchers measure

Primary outcomes

  1. inflammatory response

    determination of levels of 92 proteins in abdominal fluid and blood

    Time frame: index surgery (Groups I and II)/ emergency room (Group III)

Secondary outcomes

  1. inflammatory response in tissue

    RNA sequencing (96 spcific genes) in abdominal tissue

    Time frame: index surgery (Groups I and II)/ emergency room (Group III)

  2. microbiota composition

    PCR amplification, cloning and sequencing of genes

    Time frame: index surgery (Groups I and II)/ emergency room (Group III)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04427891
Responsible party
Eva Haglind, MD, PhD, professor (professor, Sahlgrenska University Hospital) — Principal investigator
First posted
Jun 11, 2020
Start date
Sep 21, 2021
Primary completion
Jun 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Apr 27, 2026

Study contacts

Eva Haglind, MD,PhD
principal investigator · Sahlgrenska univesitetssjukhuset

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion